发布求助
文献互助 智能选刊 最新文献

Pharmadeals Review最新文献

筛选
英文 中文
GSK’s Stiefel Laboratories Acquires Welichem Biotech’s Mid-Stage Psoriasis and Atopic Dermatitis Drug 葛兰素史克的Stiefel实验室收购Welichem生物技术公司的中期牛皮癣和特应性皮炎药物
Pharmadeals Review Pub Date : 2012-07-06 DOI: 10.3833/pdr.v2012i6.1749
Heather Cartwright
{"title":"GSK’s Stiefel Laboratories Acquires Welichem Biotech’s Mid-Stage Psoriasis and Atopic Dermatitis Drug","authors":"Heather Cartwright","doi":"10.3833/pdr.v2012i6.1749","DOIUrl":"https://doi.org/10.3833/pdr.v2012i6.1749","url":null,"abstract":"GlaxoSmithKline’s Stiefel Laboratories has agreed to acquire worldwide development and commercialisation rights to Welichem Biotech’s WBI-1001, a topical anti-inflammatory agent in Phase II development for psoriasis and atopic dermatitis. Welichem will receive an initial payment of CAD$35 M (US$34 M) and is also eligible to receive additional payments contingent upon clinical development and commercial accomplishments related to WBI-1001. The deal will initially exclude rights to the drug in China, Taiwan, Macao and Hong Kong.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80347697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Upsher-Smith to Take Over CNS Partner Proximagen Upsher-Smith将收购CNS合作伙伴Proximagen
Pharmadeals Review Pub Date : 2012-06-29 DOI: 10.3833/PDR.V2012I6.1761
Heather Cartwright
{"title":"Upsher-Smith to Take Over CNS Partner Proximagen","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I6.1761","DOIUrl":"https://doi.org/10.3833/PDR.V2012I6.1761","url":null,"abstract":"Upsher-Smith Laboratories has agreed to acquire the 84% of its CNS partner Proximagen that it does not already own in a deal worth up to £356.8 M (US$554 M). For each Proximagen share, Upsher-Smith will pay £3.20, which represents a 16% premium over Proximagen’s closing price prior to the announcement of the transaction. The deal also includes contingent value rights relating to the success of two Proximagen compounds: the Phase I vascular adhesion protein-1 (VAP1) inhibitor for rheumatoid arthritis and PRX00933, which has completed Phase II development for the treatment of obesity","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73165720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GSK Strengthens its Dermatology Business with Acquisition of Basilea’s Toctino® GSK收购巴西利亚公司的Toctino®，加强其皮肤科业务
Pharmadeals Review Pub Date : 2012-06-21 DOI: 10.3833/PDR.V2012I6.1757
Heather Cartwright
{"title":"GSK Strengthens its Dermatology Business with Acquisition of Basilea’s Toctino®","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I6.1757","DOIUrl":"https://doi.org/10.3833/PDR.V2012I6.1757","url":null,"abstract":"In exchange for £146 M (US$226 M) upfront, GlaxoSmithKline’s Stiefel Laboratories has acquired exclusive worldwide rights to Basilea Pharmaceutica’s chronic hand eczema drug Toctino® (oral alitretinoin), which is marketed in 14 countries and reported sales of CHF31 M (US$35 M) in 2011. Basilea is also entitled to receive up to an additional £50 M (US$77 M) upon US FDA approval as well as double-digit royalties beginning 3 years after launch. Basilea will use the cash proceeds from the transaction to advance its pipeline of anti-infective and oncology drugs.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"141 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76782906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Baxter Pursues Haemophilia B Gene Therapy with Chatham Therapeutics Collaboration 百特与Chatham Therapeutics合作开展血友病B基因治疗
Pharmadeals Review Pub Date : 2012-06-15 DOI: 10.3833/PDR.V2012I6.1754
Heather Cartwright
{"title":"Baxter Pursues Haemophilia B Gene Therapy with Chatham Therapeutics Collaboration","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I6.1754","DOIUrl":"https://doi.org/10.3833/PDR.V2012I6.1754","url":null,"abstract":"Baxter International has entered into an exclusive global development and commercialisation agreement with Chatham Therapeutics, an affiliate of Asklepios BioPharmaceutical, for potential treatments for haemophilia B using Chatham’s Biological Nano Particles™ gene therapy technology. Baxter has paid US$25 M upfront to advance Chatham’s haemophilia B programme through early clinical trials and has global marketing and commercialisation rights to resulting therapies.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86340530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genmab’s DuoBody™ Technology Gains Validation with Novartis Collaboration Genmab的DuoBody™技术获得诺华合作验证
Pharmadeals Review Pub Date : 2012-06-15 DOI: 10.3833/PDR.V2012I6.1753
Heather Cartwright
{"title":"Genmab’s DuoBody™ Technology Gains Validation with Novartis Collaboration","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I6.1753","DOIUrl":"https://doi.org/10.3833/PDR.V2012I6.1753","url":null,"abstract":"Genmab has formed a bispecific antibody collaboration with Novartis that is potentially worth up to US$175 M plus research funding and royalties. In return for US$2 M upfront, Genmab will create panels of bispecific antibodies to two undisclosed disease target combinations selected by Novartis using its DuoBody™ technology. The deal is the latest in a string of partnerships focused on the development of next-generation antibody therapeutics.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78550964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Galapagos Lands US$1.35 B Deal with Abbott for Phase II JAK Inhibitor Galapagos与雅培达成13.5亿美元的II期JAK抑制剂交易
Pharmadeals Review Pub Date : 2012-06-03 DOI: 10.3833/PDR.V2012I3.1693
Heather Cartwright
{"title":"Galapagos Lands US$1.35 B Deal with Abbott for Phase II JAK Inhibitor","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I3.1693","DOIUrl":"https://doi.org/10.3833/PDR.V2012I3.1693","url":null,"abstract":"Abbott has gained rights to Galapagos’ rheumatoid arthritis (RA) drug candidate GLPG0634 as part of a collaboration worth as much as US$1.35 B. Galapagos will receive US$150 M upfront and US$200 M upon successful completion of Phase II trials for RA, at which point Abbott will license the drug and assume sole responsibility for clinical development and global manufacturing. The deal ranks as the largest to date for a single Phase II asset and provides Abbott with a potential oral successor to Humira® (adalimumab).","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76821270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Actelion Gains Rights to Auxilium’s Xiaflex® in Canada, Australia, Brazil and Mexico Actelion获得Auxilium的Xiaflex®在加拿大、澳大利亚、巴西和墨西哥的权利
Pharmadeals Review Pub Date : 2012-06-03 DOI: 10.3833/PDR.V2012I3.1692
Heather Cartwright
{"title":"Actelion Gains Rights to Auxilium’s Xiaflex® in Canada, Australia, Brazil and Mexico","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I3.1692","DOIUrl":"https://doi.org/10.3833/PDR.V2012I3.1692","url":null,"abstract":"Actelion Pharmaceuticals has gained the rights to develop and commercialise Auxilium Pharmaceuticals’ Xiaflex® (collagenase clostridium histolyticum), a first-in-class biologic for Dupuytren’s contracture (DC) and Peyronie’s disease (PD), in Canada, Australia, Brazil and Mexico in a deal worth up to US$68.5 M. The drug has already received regulatory approval in the US and Europe for DC and has been accepted for review for this indication in Canada. Auxilium will continue to assume primary responsibility for the drug’s ongoing Phase III development programme for PD, data from which are expected late in the second half of 2012.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"40 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87872083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ironwood Pharmaceuticals Expands its Pipeline Beyond Linaclotide with Bionomics Deal Ironwood制药公司通过Bionomics交易扩大了利那克洛肽以外的产品线
Pharmadeals Review Pub Date : 2012-06-02 DOI: 10.3833/PDR.V2012I2.1675
Heather Cartwright
{"title":"Ironwood Pharmaceuticals Expands its Pipeline Beyond Linaclotide with Bionomics Deal","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I2.1675","DOIUrl":"https://doi.org/10.3833/PDR.V2012I2.1675","url":null,"abstract":"In order to expand its pipeline beyond the late-stage gastrointestinal drug linaclotide, Ironwood Pharmaceuticals has licensed exclusive global rights to develop and commercialise Bionomics’ Phase I anti‐anxiety compound BNC210 and other related compounds. The deal is worth up to US$345 M, including US$3 M upfront and US$10 M in near-term research funding and milestone payments, as well as royalties on sales of resulting products.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79918669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prestige Brands Agrees to Buy GSK’s Non-Core North American OTC Brands Prestige Brands同意收购GSK的北美非核心OTC品牌
Pharmadeals Review Pub Date : 2012-06-01 DOI: 10.3833/pdr.v2012i1.1646
Heather Cartwright
{"title":"Prestige Brands Agrees to Buy GSK’s Non-Core North American OTC Brands","authors":"Heather Cartwright","doi":"10.3833/pdr.v2012i1.1646","DOIUrl":"https://doi.org/10.3833/pdr.v2012i1.1646","url":null,"abstract":"In order to focus on its priority brands and emerging markets, GlaxoSmithKline (GSK) has agreed to divest 17 of its non-core consumer brands in the US and Canada to Prestige Brands for £426 M (US$661 M) in cash. The sale of the OTC brands will generate net proceeds of approximately £242 M (US$375 M), which will be returned to GSK’s shareholders during 2012. The transaction is expected to complete in the first half of 2012, subject to regulatory approvals.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"64 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85663898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Merck & Co. Licenses Exelixis’ PI3K-Delta R&D Programme 默克公司授权Exelixis的PI3K-Delta研发项目
Pharmadeals Review Pub Date : 2012-06-01 DOI: 10.3833/PDR.V2012I1.1649
Heather Cartwright
{"title":"Merck & Co. Licenses Exelixis’ PI3K-Delta R&D Programme","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I1.1649","DOIUrl":"https://doi.org/10.3833/PDR.V2012I1.1649","url":null,"abstract":"In a potential US$251 M deal, Exelixis has granted Merck & Co. worldwide rights to its preclinical PI3K-delta R&D programme, including XL499, the programme’s lead compound that has potential in the treatment of rheumatoid arthritis, allergic asthma and haematological malignancies. Merck will be solely responsible for the research, development and commercialisation of compounds originating from the programme. The agreement will provide Exelixis with resources to continue the development of its most advanced compound, cabozantinib, which is in Phase III development for medullary thyroid cancer.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"74 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79854638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信